Calliditas Announces Positive Data From Proof-of-concept Phase 2 Trial With Setanaxib
6/5 08:26
(RTTNews) - Calliditas Therapeutics (CALT) reported data from the proof-of-concept Phase 2 trial evaluating setanaxib, the company's lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck. The analysis showed st...